Ribo Submits European Clinical Trial Application for a Novel Dual…

Ribo Submits European Clinical Trial Application for a Novel Dual Targeting siRNA SR122 for Mixed and Severe Dyslipidemia, Further Strengthening Its Footprint in the Area of Lipid Disorder

Nov 9, 2026, 8:00 PM EST

Distributed by Major Health News · Originally issued via PR Newswire

Key points

Suzhou Ribo Life Science and its subsidiary Ribocure Pharmaceuticals AB announced on Nov. 9, 2026 that they have submitted a Phase I Clinical Trial Application in the EU for SR122, a siRNA therapeutic that targets both ApoC3 and PCSK9. The proposed trial would be the first clinical evaluation of SR122 in humans and would enroll healthy participants.

Ribo has submitted a Phase I Clinical Trial Application in the EU for SR122, a dual GalNAc conjugated siRNA therapeutic.
SR122 targets both ApoC3 and PCSK9 and is being developed for dyslipidemia, including severe hypertriglyceridemia (sHTG) and mixed dyslipidemia.
The planned Phase 1 study is randomized and placebo-controlled and will evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of subcutaneous SR122 in healthy participants.
Ribo is separately running Phase II clinical studies of its ApoC3-targeting siRNA RBD5044 in Europe and China.
Chief Medical Officer Dr. Anders Gabrielsen said the Phase I results will guide further development in the intended target population.

The filing concerns patients with dyslipidemia, including severe hypertriglyceridemia and mixed dyslipidemia, a condition the release links to cardiovascular disease and, in severe hypertriglyceridemia, to acute pancreatitis. If the trial proceeds, SR122 would receive its first clinical evaluation in humans. The company says the filing expands its lipid pipeline alongside ongoing Phase II studies of RBD5044 in Europe and China.

Automated summary prepared by Major Health News from the release below, which follows as issued.

SUZHOU, China and MÖLNDAL, Sweden, Nov. 9, 2026 — Suzhou Ribo Life Science (06938.HK) and its subsidiary Ribocure Pharmaceuticals AB (collectively referred to as "Ribo") announced the submission of a Phase Ⅰ Clinical Trial Application (CTA) in EU for SR122, a dual GalNAc conjugated siRNA therapeutic being developed for the treatment of dyslipidemia, including severe hypertriglyceridemia (sHTG) and mixed dyslipidemia.

As Ribo progresses the Phase II clinical studies of RBD5044 — its core lipid asset and the world's second-most advanced ApoC3-targeting siRNA — in Europe and China, this filing marks a further upgrade to its lipid pipeline strategy and a key step in solidifying its leading position in lipid disorders.

SR122 simultaneously targets ApoC3 and PCSK9, two clinically validated pathways that play complementary roles in lipid metabolism. By addressing both triglyceride-rich lipoproteins and low-density lipoprotein cholesterol (LDL-C), SR122 has the potential to provide a differentiated treatment approach with durable improvements across multiple lipid parameters and cardiometabolic risk factors.

Dyslipidemia remains a major global health challenge and a key driver of cardiovascular disease, the leading cause of death worldwide. Patients with mixed dyslipidemia often continue to face substantial residual cardiovascular risk despite currently available lipid-lowering therapies, while individuals with severe hypertriglyceridemia are also at increased risk of acute pancreatitis.

The Phase 1 clinical trial is a randomized, placebo-controlled study designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of subcutaneously administered SR122 in healthy participants. The study will provide the first clinical evaluation of the dual targeting SR122 approach in humans and generate key data to support further development.

"The simultaneous knockdown of ApoC3 and PCSK9 provides superior synergy in reducing overwhelming lipid risk in severe hypertriglyceridemia and represent a step change in patient risk management through inhibition of complementary mechanisms. The results of the Phase Ⅰ trial will be guiding the further advancement through clinical development in the intended target population." said Dr. Anders Gabrielsen, Chief Medical Officer of Ribo.

SOURCE Suzhou Ribo Life Science Co., Ltd.